

# A randomised controlled trial of Permacol® reinforcement of permanent stomas versus standard technique in reduction of parastomal hernia

<b>Submission date</b> 12/07/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 11/08/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 25/09/2013	<b>Condition category</b> Digestive System	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Ms Tina Jane Adams

### Contact details

Tissue Science Laboratories  
Victoria House  
Victoria Road  
Aldershot  
Hampshire  
United Kingdom  
GU11 1EJ

## Additional identifiers

### Protocol serial number

RL100

## Study information

## **Scientific Title**

### **Acronym**

PROPHECI

### **Study objectives**

Our hypothesis is that reinforcing the stoma trephine with Permacola® when the stoma is being formed is superior to the standard technique without reinforcement in terms of preventing herniation, and the use of Permacol® is associated with less morbidity, infection and pain.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved by the Huntingdon Research Ethics Committee on 30/05/2006 (reference number: 06/Q0104/32).

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Parastomal herniation

### **Interventions**

We intend to randomise a cohort of patients who are undergoing permanent stoma formation for a variety of elective procedures between collagen mesh reinforcement of the stoma versus no mesh as control.

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

Permacola®

### **Primary outcome(s)**

1. To determine the efficacy of Permacol® in reducing the incidence of parastomal hernia
2. To test whether the use of collagen mesh reinforcement is associated with lower rates of clinical herniation than no reinforcement. This will be evaluated at discharge and one, six, 12, 18 and 24 months post-operatively.

**Key secondary outcome(s)**

The secondary objectives of the study will be to determine differences in:

1. The radiological incidence of herniation as detected by Computerised Tomography (CT) scan and correlate this with the primary objective at 12 months
2. Complications associated with the technique used for the reinforcement. These will be evaluated at discharge and one, six, 12, 18 and 24 months post-operatively.
3. The handling characteristics, ease of insertion and suturing of the implant will be evaluated by the surgeon
4. Cost-benefit analysis comparing the cost of the reinforcement technique and the length of stay
5. Quality of life assessed using short-form-36 questionnaire (SF36) version two and EuroQol EQ-5D before and at one, six, 12, 18 and 24 months post-operatively

**Completion date**

01/08/2009

**Eligibility****Key inclusion criteria**

1. Requirement of an elective permanent stoma due to bowel disease
2. Written informed consent
3. Must be aged 18 -100 years and agree to the randomised procedure
4. If of childbearing potential, must have given a negative pregnancy test

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Key exclusion criteria**

1. If participant is taking part in another clinical study, which directly relates to this study
2. Suffering from an untreated metabolic or systemic illness (e.g. diabetes or rheumatoid arthritis or any immunological disease)
3. A diagnosis of mentally limiting conditions such as Alzheimer's or mental retardation or is unable to understand all study requirements

4. Is allergic to any porcine or collagen products
5. Has any indication of a Methicillin-Resistant Staphylococcus Aureus (MRSA) infection
6. Any indication of abdominal wall sepsis

**Date of first enrolment**

01/07/2006

**Date of final enrolment**

01/08/2009

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Tissue Science Laboratories**

Hampshire

United Kingdom

GU11 1EJ

## Sponsor information

**Organisation**

Tissue Science Laboratories plc (UK)

**ROR**

<https://ror.org/020hbh524>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Tissue Science Laboratories plc (UK)

## Results and Publications

## **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration